A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT ID: NCT03148418
Last Updated: 2026-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
382 participants
INTERVENTIONAL
2017-09-20
2030-03-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
NCT06331598
Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
NCT03465891
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03369964
The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL
NCT03463057
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
NCT00275431
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atezolizumab Monotherapy
Participants will continue to receive atezolizumab monotherapy in a Genentech or Roche-sponsored study (the parent study) in accordance with local prescribing information till the participant continues to derive clinical benefit or until death, withdrawal of study consent, unacceptable toxicity, pregnancy, participant non-compliance, or study termination by the Sponsor, whichever occurs first.
Atezolizumab
Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
Combined Agents with Atezolizumab
Participants will receive treatment of atezolizumab with combined agent(s) as directed per the parent study. Participants will receive agent(s) in combination with atezolizumab at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
Atezolizumab
Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
Bevacizumab
Bevacizumab will be administered as directed per the parent study.
Comparator Treatment
Participants will receive comparator treatment administration as directed per the parent study. Participants will receive comparator treatment at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
Bevacizumab
Bevacizumab will be administered as directed per the parent study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab
Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
Bevacizumab
Bevacizumab will be administered as directed per the parent study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eligible for continuing or crossing over to atezolizumab-based therapy at the time of the parent-study closure as per the parent study or eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study at the time of the parent-study closure as per the parent study, with no access to commercially available comparator agent
* First dose of study treatment in the extension study will be received within 7 days of the treatment interruption window allowed by the parent study
* Continue to benefit from atezolizumab-based study treatment or from the comparator at the time of parent-study closure as assessed by the investigator
* Negative serum pregnancy test within 7 days prior to start of study treatment in women of childbearing potential
Specific criteria for patients from the IMpower133 parent study only who do not continue treatment in the extension study and/or receive commercially available atezolizumab (Tecentriq) outside this extension study and continue safety and survival follow-up only in the extension study:
\- Discontinuation of atezolizumab-based therapy in the IMpower133 parent study and in survival follow- up at the time of IMpower133 parent study closure, or eligible for continuing or crossing over to atezolizumab-based therapy as per the IMpower133 parent protocol and have access to commercially available atezolizumab (Tecentriq) outside this extension study at the time of the IMpower133 parent-study closure
Exclusion Criteria
* Meet of any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in the extension study
* Study treatment is commercially marketed in the patient's country for the patient specific disease and is accessible to the patient
* Time between the last dose of treatment received in parent study and first dose in extension study is longer than the interruption period (± 7 days) allowed in the parent study
* Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in the extension study
* Permanent discontinuation of atezolizumab for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in the extension study (if applicable)
* Any unresolved or irreversible toxicities during the parent study that required permanent discontinuation of study treatment, in accordance to the parent study or local prescribing information
* Ongoing SAE(s) that has not resolved to baseline level or Grade less than or equal to (\<=) 1 from the parent study or during the time between last treatment in the parent study and the first dose of study treatment in the extension study
* Any serious uncontrolled concomitant disease that would contraindicate the use of study treatment at the time of the extension study or that would place the participant at high risk for treatment-related complications
* Concurrent participation in any therapeutic clinical trial (other than the parent study)
Specific criteria for patients who do not continue treatment in the extension study and/or receive commercially available atezolizumab (Tecentriq) outside this extension study and continue safety and survival follow-up only in the extension study:
\- Discontinuation of comparator in parent study and in survival follow-up at the time of parent study closure
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HonorHealth Research Institute ? Bisgrove
Scottsdale, Arizona, United States
Angeles Clinic & Rsch Inst
Los Angeles, California, United States
UCLA
Los Angeles, California, United States
Kaiser Permanente - San Diego (Zion Ave)
San Marcos, California, United States
University Of Colorado
Aurora, Colorado, United States
Rocky Mountain Cancer Ctr - Denver (Williams)
Denver, Colorado, United States
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut, United States
Georgetown University Medical Center Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Florida Cancer Specialists - Fort Myers (Broadway)
Fort Myers, Florida, United States
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States
Florida Cancer Specialists.
St. Petersburg, Florida, United States
H. Lee Moffitt Cancer Center and Research Inst.
Tampa, Florida, United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
Marietta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
University Of Chicago Medical Center
Chicago, Illinois, United States
Ingalls Memorial Hospital
Harvey, Illinois, United States
Illinois Cancer Care
Peoria, Illinois, United States
New England Cancer Specialists
Westbrook, Maine, United States
Johns Hopkins Univ Med Center
Baltimore, Maryland, United States
Maryland Oncology Hematology, P.A.
Columbia, Maryland, United States
Massachusetts General Hospital.
Boston, Massachusetts, United States
Beth Israel Medical Center
Boston, Massachusetts, United States
Dana Farber Cancer Inst.
Boston, Massachusetts, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
US oncology research at Minnesota Oncology
Saint Louis Park, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Comprehensive Cancer Centers of Nevada - Eastern Avenue
Las Vegas, Nevada, United States
Summit Medical Center
Florham Park, New Jersey, United States
New York Oncology Hematology, P.C.
Albany, New York, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Carolina BioOncology Institute, PLCC
Huntersville, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
Oncology Associates of Oregon, P.C
Eugene, Oregon, United States
Northwest Cancer Specialists - Portland (N Broadway)
Portland, Oregon, United States
Penn State Hershey Cancer Institute
Hershey, Pennsylvania, United States
Allegheny Cancer Center
Pittsburgh, Pennsylvania, United States
Sarah Cannon Res Inst
Nashville, Tennessee, United States
Texas Oncology - DFW
Dallas, Texas, United States
Tyler Cancer Center
Tyler, Texas, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
Blue Ridge Cancer Care
Roanoke, Virginia, United States
University of Washington Seattle Cancer Care Alliance
Seattle, Washington, United States
Northwest Medical Specialties
Tacoma, Washington, United States
Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, , Argentina
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Princess AleXandra Hospital
Woolloongabba, Queensland, Australia
Klinik Penzing
Vienna, , Austria
Krankenhaus Nord - Klinik Floridsdorf
Vienna, , Austria
AZ Glorieux- vzw Werken Glorieux
Ronse, , Belgium
ZAS Sint Augustinus Wilrijk
Wilrijk, , Belgium
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
Fundacao Antonio Prudente
São Paulo, São Paulo, Brazil
Multiprofile Hospital for Active Treatment Serdika EOOD
Sofia, , Bulgaria
Royal Victoria Hospital
Barrie, Ontario, Canada
William Osler Health Centre
Brampton, Ontario, Canada
Lakeridge Health Corporation-Oshawa
Oshawa, Ontario, Canada
Sunnybrook Odette Cancer Centre
Toronto, Ontario, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Cite de La Sante de Laval
Laval, Quebec, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Bradford Hill Centro de Investigaciones Clinicas
Recoleta, , Chile
Masarykuv onkologicky ustav
Brno, , Czechia
Thomayerova nemocnice
Praha 4 - Krc, , Czechia
Hopital Jean Minjoz
Besançon, , France
Chu Grenoble - Hopital Albert Michallon
Grenoble, , France
Centre Leon Berard
Lyon, , France
Hopital Nord
Marseille, , France
Centre René Gauducheau - cancer Nantes - Atlantique
Nantes, , France
Centre Antoine Lacassagne, Centre de Lutte Contre le Cancer (CLCC) de Nice
Nice, , France
Hopital Saint Louis
Paris, , France
GH Paris Saint Joseph
Paris, , France
Hopital Tenon
Paris, , France
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
CH de Saint Quentin
Saint-Quentin, , France
Centre Medico-Chirurgical Foch
Suresnes, , France
CHU de Toulouse - Hôpital Larrey
Toulouse, , France
Institut Gustave Roussy
Villejuif, , France
Klinikum d.Universität München Campus Großhadern
München, , Germany
Semmelweis Egyetem X
Budapest, , Hungary
Református Pulmonológiai Centrum
Törökbálint, , Hungary
Belinson Medical Center
Petah Tikva, , Israel
Azienda Osp Uni Seconda Università Degli Studi Di Napoli
Napoli, Campania, Italy
Azienda Ospedaliera A. Cardarelli
Napoli, Campania, Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
Napoli, Campania, Italy
A.O. Universitaria Policlinico Di Modena
Modena, Emilia-Romagna, Italy
Università Cattolica Del S Cuore
Rome, Lazio, Italy
IRCCS AOU San Martino - IST
Genoa, Liguria, Italy
ASL 3 Genovese
Genoa, Liguria, Italy
Irccs Istituto Nazionale Dei Tumori (Int)
Milan, Lombardy, Italy
Irccs Istituto Europeo Di Oncologia (IEO)
Milan, Lombardy, Italy
Asst Di Monza
Monza, Lombardy, Italy
A.O.U. Maggiore della Carità
Novara, Piedmont, Italy
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Orbassano, Piedmont, Italy
Policlinico Vittorio Emanuele
Catania, Sicily, Italy
Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato
Arezzo, Tuscany, Italy
A.O. Universitaria Pisana-Ospedale Cisanello
Pisa, Tuscany, Italy
Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica
Siena, Tuscany, Italy
Ospedale Santa Maria Della
Perugia, Umbria, Italy
IOV - Istituto Oncologico Veneto - IRCCS
Padua, Veneto, Italy
Shikoku Cancer Center
Ehime, , Japan
Sendai Kousei Hospital
Miyagi, , Japan
Niigata Cancer Center Hospital
Niigata, , Japan
Iwate Medical University Hospital
Numakunai, , Japan
Okayama University Hospital
Okayama, , Japan
Toranomon Hospital
Tokyo, , Japan
The Cancer Institute Hospital of JFCR, Respiratory Medicine
Tokyo, , Japan
Wakayama Medical University Hospital
Wakayama, , Japan
NKI/AvL
Amsterdam, , Netherlands
Auckland city hospital
Auckland, , New Zealand
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
Gdansk, , Poland
Oddzia? Onkologii Klinicznej i Chemioterapii Szpitala ELBL?SKA
Warsaw, , Poland
Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad
Warsaw, , Poland
Hospital de Santa Maria
Lisbon, , Portugal
Centro Hospitalar do Porto ? Hospital de Santo António
Porto, , Portugal
Institut Oncologic Ion Chiricuta
Cluj-Napoca, , Romania
ONCOMED - Medical Centre
Timișoara, , Romania
Moscow City Oncology Hospital #62
Moscovskaya Oblast, Moscow Oblast, Russia
Clinic for Pulmonology, Clinical Center of Serbia
Belgrade, , Serbia
University Hospital Medical Center Bezanijska kosa
Belgrade, , Serbia
Institute of Oncology Ljubljana
Ljubljana, , Slovenia
National Cancer Center
Gyeonggi-do, , South Korea
Seoul National University Bundang Hospital
Gyeonggi-do, , South Korea
Chonnam National University Hwasun Hospital
Jeollanam-do, , South Korea
Samsung Medical Center
Seoul, , South Korea
Hospital Son Llatzer
Palma de Mallorca, Balearic Islands, Spain
Hospital Universitario Reina Sofia
Córdoba, Cordoba, Spain
Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología
A Coruña, LA Coruna, Spain
Hospital Universitario Materno Infantil de Gran Canaria
Las Palmas de Gran Canaria, LAS Palmas, Spain
Clinica Universitaria de Navarra
Pamplona, Navarre, Spain
Hospital del Mar
Barcelona, , Spain
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, , Spain
Hospital Clinic de Barcelona. Unidad de Nuevas Terapias
Barcelona, , Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Institut Catala d Oncologia Hospital Duran i Reynals
Barcelona, , Spain
Hospital Universitari Germans Trias i Pujol
Barcelona, , Spain
Hospital San Pedro De Alcantara
Cáceres, , Spain
Complejo Hospitalario de Jaen
Jaén, , Spain
Hospital Lucus Augusti
Lugo, , Spain
Hospital General Universitario Gregorio Marañon
Madrid, , Spain
Hospital Ramon y Cajal
Madrid, , Spain
Hospital Universitario Clínico San Carlos
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital de Madrid Norte Sanchinarro- Centro Integral Oncologico Clara Campal
Madrid, , Spain
Hospital Regional Universitario Carlos Haya
Málaga, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Hospital General Universitario de Valencia
Valencia, , Spain
Hospital NisA 9 de Octubre
Valencia, , Spain
CHUV
Lausanne, , Switzerland
Changhua Christian Hospital
Changhua, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
National Taiwan Uni Hospital
Taipei, , Taiwan
Chulalongkorn Hospital
Bangkok, , Thailand
Ramathibodi Hospital
Bangkok, , Thailand
Faculty of Med. Siriraj Hosp.
Bangkok, , Thailand
Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi
Edirne, , Turkey (Türkiye)
Istanbul Uni Cerrahpasa Medical Faculty Hospital
Istanbul, , Turkey (Türkiye)
Hacettepe Uni Medical Faculty Hospital
S?hhiye, Ankara, , Turkey (Türkiye)
Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU
Dnipropetrovsk, , Ukraine
Barts & London School of Med
London, , United Kingdom
Royal Free Hospital
London, , United Kingdom
St George's Hospital
London, , United Kingdom
Royal Marsden Hospital - London
London, , United Kingdom
Charing Cross Hospital
London, , United Kingdom
Christie Hospital NHS Trust
Manchester, , United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
Metropolitan Borough of Wirral, , United Kingdom
Nottingham City Hospital
Nottingham, , United Kingdom
Royal Marsden Hospital - Surrey
Surrey, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F, de Castro G Jr, Havel L, Bernabe Caro R, Losonczy G, Lee JS, Kowalski DM, Andric Z, Califano R, Veatch A, Gerstner G, Batus M, Morris S, Kaul M, Cuchelkar V, Li H, Danner BJ, Nabet BY, Liu SV. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study. Lung Cancer. 2024 Oct;196:107924. doi: 10.1016/j.lungcan.2024.107924. Epub 2024 Aug 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-005189-75
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
BO39633
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.